The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
The move strengthens GBL’s clinical-stage presence in the United States
India plays a critical role in Bristol Myers Squibb’s global strategy
Clinical trial enrollment has long been a bottleneck in drug development
Ryght AI tackles these hurdles with its AI Site Twin platform
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Subscribe To Our Newsletter & Stay Updated
